What the work involves

This is a one-sitting research study, not an ongoing evaluation contract. You complete a structured online survey of roughly 30 minutes that walks through how you reason about systemic therapy in metastatic prostate cancer — likely covering sequencing in mHSPC versus mCRPC, how you weigh ARPI intensification, docetaxel, PARP inhibitors, radioligand therapy and genomic testing results, and what patient or disease factors push you one way rather than another. Expect a mix of closed-response items and free-text where your clinical rationale matters more than the option you picked. The output feeds an AI research lab's work on healthcare tools, so the value sits in the reasoning you show, not in matching a guideline answer.

What the platform screens for

Mercor's screen is verification-led. It confirms MD or DO, active board certification, an unrestricted US license, and that you practice primarily in the United States. Beyond credentials, it probes recency and volume: have you cared for prostate cancer patients in the past 12 months, including at least one with mHSPC or mCRPC, and do you hold primary or shared responsibility for selecting systemic treatment? At least 25% of your professional time must be direct patient care — pure research, administrative or industry roles do not qualify.

There are hard exclusions. The study is closed to anyone who participated in prostate-cancer market research in the past three months, and to anyone who — or whose immediate family member — works for a pharmaceutical, diagnostics, market research or advertising company, a wholesaler, or a specialty pharmacy. These are asked directly and are not negotiable.

Logistics

  • Remote, US-based participants only
  • Fully asynchronous: complete the survey at any time within the stated window
  • Single session, approximately 30 minutes, completed independently
  • One-time payment observed at $175, released after the submission passes verification
  • No ongoing commitment implied; some participants are contacted about later studies, but nothing is guaranteed